However, direct targeting of NF-κB for cancer therapy still faces enormous challenges and most of these strategies remain thus far confined to the pre-clinical stage and very few of them have entered clinical trials for pancreatic cancer therapy (Carbone and Melisi, 2012). Here, NFKB1 is linked to pancreatic neoplasm.